Maravai Lifesciences Gets RS Rating Upgrade, Hitting 70+

In a welcome move, Maravai Lifesciences (MRVI) saw its Relative Strength Rating improve from 65 to 73 on Tuesday.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary rating tracks share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price movement over the last 52 weeks stacks up against all the other stocks in our database.

Decades of market research reveals that the market’s biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if Maravai Lifesciences can continue to show renewed price strength and hit that benchmark.

Looking For Winning Stocks? Try This Simple Routine

Maravai Lifesciences is not currently near a potential buying area. See if the stock goes on to form a promising consolidation that could spark a new run.

Earnings grew 167% last quarter, up from 0% in the prior report. Revenue also increased, from 173% to 191%. The company is expected to report its latest earnings and sales numbers on or around Jul. 28.

The company earns the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN) and Avid Bioservices (CDMO) are also among the group’s highest-rated stocks.


Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders


Most Related Links :
verity news now Governmental News Finance News

Source link

Back to top button